secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001503274-25-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q4 2024 revenue $35.2M (+11% YoY); FY 2025 guidance $140-146M
-----------------------------------------------------------------------

- Q4 revenue $35.2M, up 11% YoY; net loss $11.6M vs $8.8M prior year.
- Full-year 2024 revenue $137.4M (+12%); net loss $38.5M improved $10.2M.
- Ended 2024 with $291.7M cash; 2025 cash usage guided at $55-65M (incl. $20M EMISSION payment).
- FY 2025 revenue outlook $140-146M (2-6% growth) excluding Lucent Diagnostics and Akoya impact.
- Simoa ONE instrument launch planned by end-2025; FDA breakthrough designation for LucentAD Complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/0001503274-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/qtrx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001503274-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer